Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neoprobe Appoints VP, Pharmaceutical Research & Clinical Development
Cope also served for a number of years as the Ernest W. Volwiler Fellow and head, cancer and AIDS research effort for Abbot Laboratories-Ross Division. Cope is active
Cope also served for a number of years as the Ernest W. Volwiler Fellow and head, cancer and AIDS research effort for Abbot Laboratories-Ross Division. Cope is active
The data show that treatment with cyclopamine, the natural product foundation of IPI-926, in animals bearing grafts of primary ovarian cancer resulted in significant tumor growth inhibition compared
Dr Rava comes to Artemis after 16 years at Affymetrix where he was a scientific co-founder and most recently senior vice president of R&D. Dr Rava has received
The company believes the decline in sales is related to customers tumbling their capital expenditures as a result of the changes in the global economy. The anticipated revenue
Since joining 3SBio in October 2008, Mr Tan has been acting as the financial advisor for the company, providing advice on the company’s capital market initiatives and overseeing
Mr Larochelle will remain on the board of directors of Adaltis and will ensure a smooth executive leadership transition, working with Mr Bambic in his new role. Most
The 500mg single-dose vial expands Sagent’s existing line of cefazolin products beyond the 1gm single-dose vials and 10gm pharmacy bulk package vials launched in March 2008. All doses
A division of cancer treatment and diagnosis-sponsored Phase I clinical trial is expected to be initiated to evaluate dose and safety of GDC-0449 in pediatric patients with medulloblastoma.
According to the company, this new system requires no coding, displays results in seven seconds, requires a tiny 0.3 micro liter sample size, and was developed to use
The acquisition gains PPD immediate entry into Romania, Bulgaria, Serbia and Croatia with established infrastructure and expertise, and also bolsters PPD’s existing staff and operations in Poland, Russia